Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Updates (for clubhouse)

<< Previous

Bullboard Posts

Next >>

Post by Pragmatiston Feb 26, 2021 1:40pm

285 Views

Post# 32672496

Updates (for clubhouse)

That adware sure gets in the way of completing some posts...

The numbers I quoted came from the Prospectus Supplement date 19 Feb

The syndicate composition and broker warrant details were in the Underwirter Agreement dated Feb 19.

The brokers should be aligned with SHs in the longer term as they now hold warrants. You probalby observed that 4 out of 5 of Antibe's analysts come from the firms included in the syndicate.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec